Millington Financial Advisors’s Gain Therapeutics GANX Stock Holding History

Millington Financial Advisors’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.3K	Buy	+15,000	New	+$32.6K	0.01%	118

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Millington Financial Advisors's GANX Position: Q1 2026 in Review

Millington Financial Advisors opened a new position in Gain Therapeutics (GANX) in Q1 2026: 15,000 shares worth $29.3K. The stake represents 0.01% of the portfolio and ranks #118 among its holdings.

42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Millington Financial Advisors held 15,000 shares of Gain Therapeutics worth $29.3K as of Q1 2026.
Gain Therapeutics was a new Millington Financial Advisors position in Q1 2026.
Gain Therapeutics made up 0.01% of Millington Financial Advisors's portfolio in Q1 2026, its #118 holding.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Millington Financial Advisors's 13F filing for Q1 2026, filed 8 May 2026.